TheraVet SA Logo

TheraVet SA

Veterinary biotech firm developing treatments for osteoarticular diseases in pets.

ALVET | BR

Overview

Corporate Details

ISIN(s):
BE0974387194
LEI:
984500804EBR3F1EFF71
Country:
Belgium
Address:
Avenue Jean Mermoz 32, 6041 Charleroi

Description

TheraVet SA is a veterinary biotechnology company specializing in the development and commercialization of treatments for osteoarticular diseases in companion animals. The company focuses on creating a portfolio of pharmaceutical products and solutions designed to manage bone and joint conditions, such as osteoarthritis. Its primary objective is to provide innovative therapeutic options to improve the mobility and quality of life for pets.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-07 19:57
Informations privilégiées / Autres communiqués
French 197.8 KB
2025-03-07 19:57
Informations privilégiées / Autres communiqués
French 197.8 KB
2025-03-07 00:00
20250307CA _EGEIRO CP eng.pdf
English 183.2 KB
2025-03-07 00:00
20250307 CA_EGEIRO CP.pdf
French 187.0 KB
2025-01-28 16:00
Inside Information / Other news releases
English 200.0 KB
2025-01-28 16:00
Informations privilégiées / Autres communiqués
French 203.1 KB
2025-01-27 00:00
CP 20250127 EURONEXT qualification apport actif H4 acquisition inversée.pdf
French 644.6 KB
2025-01-27 00:00
CP 20250127 EURONEXT qualification apport actif H4 acquisition inversée.pdf
French 644.6 KB
2024-12-12 18:00
Informations privilégiées / Autres communiqués
French 193.7 KB
2024-12-12 00:00
CP_EGEIRO-121224_notification_de_transparence_ARTICLE 14.pdf
French 193.7 KB
2024-12-05 18:00
Informations privilégiées / Autres communiqués
French 182.9 KB
2024-11-18 18:00
Inside Information / Other news releases
English 191.3 KB
2024-11-18 18:00
Informations privilégiées / Autres communiqués
French 165.7 KB
2024-11-18 00:00
EGEIRO-181124_CP démission EB.pdf
French 165.7 KB
2024-10-29 07:30
Inside Information / Other news releases
English 257.0 KB

Automate Your Workflow. Get a real-time feed of all TheraVet SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TheraVet SA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TheraVet SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-11-21 Bastianelli Enrico Board Other 200,000 380,000.00 EUR

Peer Companies

BELITE BIO, INC Logo
Clinical-stage biopharma developing therapies for retinal and metabolic diseases.
United States of America
BLTE
Benitec Biopharma Inc. Logo
A clinical-stage biotech developing genetic medicines to silence disease-causing genes.
United States of America
BNTC
BeOne Medicines Ltd. Logo
Global oncology company that discovers, develops, and delivers cancer treatments.
United States of America
ONC
BerGenBio Logo
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
Norway
BGBIO
Beximco Pharmaceuticals Ltd. Logo
Manufacturer of generic drugs, APIs, and specialized products for global markets.
Bangladesh
BXP
BeyondSpring Inc. Logo
Clinical-stage biopharma company developing immuno-oncology cancer therapies.
United States of America
BYSI
BGM Group Ltd. Logo
A holding company focused on technology and biopharmaceutical manufacturing.
United States of America
BGM
Bicara Therapeutics Inc. Logo
Clinical-stage biopharma developing dual-action biologics for solid tumors.
United States of America
BCAX
BICYCLE THERAPEUTICS PLC Logo
Clinical-stage biopharma developing a novel class of bicyclic peptide medicines.
United States of America
BCYC
BIFIDO. Co. Ltd Logo
Biotechnology firm developing human-derived Bifidobacterium for various products.
South Korea
238200

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.